Evidence map›Paper›PMID 33813118›Full record

ArticleClinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases2021

Recommendations for accurate genotyping of SARS-CoV-2 using amplicon-based sequencing of clinical samples.

Slawomir Kubik, Ana Claudia Marques, Xiaobin Xing, Janine Silvery, Claire Bertelli, Flavio De Maio, Spyros Pournaras, Tom Burr, Yannis Duffourd, Helena Siemens and 19 more

Open access · hybridAbstract read
In one paragraph

Article in Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
2.4field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 42 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. A simplified alternative diagnostic algorithm for SARS-CoV-2 suspected symptomatic patients and confirmed close contacts (asymptomatic): A consensus of Latin American experts.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2022
    Article
  13. Article
  14. Article
  15. Article
  16. Mutation profile of SARS-CoV-2 genome in a sample from the first year of the pandemic in Colombia.Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases · 2022
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors at 12 institutions in 8 countries.

Slawomir KubikSOPHiA GENETICS, Chemin des Mines 9, CH-1202 Geneva, Switzerland.
Ana Claudia MarquesSOPHiA GENETICS, Rue Du Centre 172, CH-1025 Saint Sulpice, Switzerland.
Xiaobin XingSOPHiA GENETICS, Rue Du Centre 172, CH-1025 Saint Sulpice, Switzerland.
Janine SilveryLABCON-OWL Analytik, Forschung und Consulting GmbH, Siemensstraße 40, 32105 Bad Salzuflen, Germany.
Claire BertelliGenomics and Metagenomics Laboratory, Institute of Microbiology, Lausanne University Hospital and University of Lausanne, Bugnon 48, 1011 Lausanne, Switzerland.
Flavio De MaioFondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica Del Sacro Cuore, L.go Agostino Gemelli 8, 00168 Roma, Italy.
Spyros PournarasLaboratory of Clinical Microbiology, Attikon University Hospital Medical School, National and Kapodistrian University of Athens, Athens, Rimini 1, Chaidari 124 62, Greece.
Tom BurrSource BioScience, Units 24/25, William James House, Cowley Road, Cambridge, CB4 0WU, United Kingdom.
Yannis DuffourdEquipe GAD - Inserm U1231, CHU François Mitterrand, 21000 Dijon, France.
Helena SiemensLABCON-OWL Analytik, Forschung und Consulting GmbH, Siemensstraße 40, 32105 Bad Salzuflen, Germany.
Chakib AllouiLaboratoire de Virologie, CHU Avicenne, AP-HP, 93000 Bobigny, France.
Lin SongSOPHiA GENETICS, Rue Du Centre 172, CH-1025 Saint Sulpice, Switzerland.
Yvan WengerSOPHiA GENETICS, Chemin des Mines 9, CH-1202 Geneva, Switzerland.
Alexandra SaittaSOPHiA GENETICS, Chemin des Mines 9, CH-1202 Geneva, Switzerland.
Morgane MacheretSOPHiA GENETICS, Chemin des Mines 9, CH-1202 Geneva, Switzerland.
Ewan W SmithSOPHiA GENETICS, Chemin des Mines 9, CH-1202 Geneva, Switzerland.
Philippe MenuSOPHiA GENETICS, Rue Du Centre 172, CH-1025 Saint Sulpice, Switzerland.
Marion BrayerSOPHiA GENETICS, Rue Du Centre 172, CH-1025 Saint Sulpice, Switzerland.
Lars M SteinmetzStanford Genome Technology Center, Stanford University, Palo Alto, CA, USA.
Ali Si-MohammedLaboratoire de Virologie, CHU François Mitterrand, 2, Rue Angélique Ducoudray, 2100 Dijon, France.
Josiane ChuisseuSource BioScience, Units 24/25, William James House, Cowley Road, Cambridge, CB4 0WU, United Kingdom.
Richard StevensSource BioScience, Units 24/25, William James House, Cowley Road, Cambridge, CB4 0WU, United Kingdom.
Pantelis ConstantoulakisBioAnalytica Genotypos SA, 3-5 Ilision Str, 115 28 Athens, Greece.
Michela SaliDipartimento di Scienze Biotecnologiche di Base, Cliniche Intensivologiche e Perioperatorie - Sezione di Microbiologia, Università Cattolica Del Sacro Cuore, Rome, Italy.
Gilbert GreubGenomics and Metagenomics Laboratory, Institute of Microbiology, Lausanne University Hospital and University of Lausanne, Bugnon 48, 1011 Lausanne, Switzerland.
Carsten TiemannLABCON-OWL Analytik, Forschung und Consulting GmbH, Siemensstraße 40, 32105 Bad Salzuflen, Germany.
Vicent PelechanoSciLifeLab, Department of Microbiology, Tumour and Cell Biology, Karolinska Institutet, 17165 Solna, Sweden.
Adrian WilligSOPHiA GENETICS, Chemin des Mines 9, CH-1202 Geneva, Switzerland.
Zhenyu XuSOPHiA GENETICS, Rue Du Centre 172, CH-1025 Saint Sulpice, Switzerland. Electronic address: zxu@sophiagenetics.com.
Sophia Genetics (Switzerland) · CHSource BioScience (United Kingdom) · GBLaboratory Krone · DEUniversity of Lausanne · CHAgostino Gemelli University Polyclinic · ITHôpital Avicenne · FRInserm · FRNational and Kapodistrian University of Athens · GRScience for Life Laboratory · SESiemens (Germany) · DEStanford University · USUniversità Cattolica del Sacro Cuore · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesGenotyping of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been instrumental in monitoring viral evolution and transmission during the pandemic. The quality of the sequence data obtained from these genotyping efforts depends on several factors, including the quantity/integrity of the input material, the technology, and laboratory-specific implementation. The current lack of guidelines for SARS-CoV-2 genotyping leads to inclusion of error-containing genome sequences in genomic epidemiology studies. We aimed to establish clear and broadly applicable recommendations for reliable virus genotyping.

methodsWe established and used a sequencing data analysis workflow that reliably identifies and removes technical artefacts; such artefacts can result in miscalls when using alternative pipelines to process clinical samples and synthetic viral genomes with an amplicon-based genotyping approach. We evaluated the impact of experimental factors, including viral load and sequencing depth, on correct sequence determination.

resultsWe found that at least 1000 viral genomes are necessary to confidently detect variants in the SARS-CoV-2 genome at frequencies of ≥10%. The broad applicability of our recommendations was validated in over 200 clinical samples from six independent laboratories. The genotypes we determined for clinical isolates with sufficient quality cluster by sampling location and period. Our analysis also supports the rise in frequencies of 20A.EU1 and 20A.EU2, two recently reported European strains whose dissemination was facilitated by travel during the summer of 2020.

conclusionsWe present much-needed recommendations for the reliable determination of SARS-CoV-2 genome sequences and demonstrate their broad applicability in a large cohort of clinical samples.

Indexed as

ArtifactsCOVID-19Genome, ViralGenotyping TechniquesGuidelines as TopicHigh-Throughput Nucleotide SequencingHumansReproducibility of ResultsRNA, ViralSARS-CoV-2Sensitivity and SpecificityWhole Genome SequencingWorkflowRNA, ViralAmpliconCoronavirusGenomeGenotypingGuidelinesNext-generation sequencingNGSRecommendationsSARS-CoV-2

Identifiers

PMID33813118
PMCPMC8016543
OpenAlexW3145779445

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.